Nervgen Pharma Corp - NGENF STOCK NEWS

Welcome to our dedicated page for Nervgen Pharma news (Ticker: NGENF), a resource for investors and traders seeking the latest updates and insights on Nervgen Pharma stock.

NervGen Pharma Corp (symbol: NGENF) is a clinical-stage biotech company focused on developing cutting-edge solutions for treating nervous system damage. Their lead drug candidate, NVG-291, is currently in a Phase 1b/2a clinical trial, targeting spinal cord injury as the initial indication. The company recently reported its financial and operational results, highlighting progress in recruitment for their clinical study and receiving Fast Track designation from the FDA. With a strong focus on innovative treatments and dedicated research efforts, NervGen is committed to enabling the nervous system to repair itself in cases of injury or disease.

10/17/2023 08:00 AM

News

NervGen Pharma Appoints John Ruffolo to Board of Directors

Rhea-AI Summary

NervGen Pharma appoints John Ruffolo, Founder and Managing Partner of Maverix Private Equity, to its Board of Directors. Ruffolo brings extensive experience in private equity and venture capital, as well as personal knowledge of spinal cord injury. NervGen is currently conducting a clinical trial for its drug NVG-291 for spinal cord injury treatment.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

1.87%

Tags

09/25/2023 08:30 AM

News

NervGen Pharma Announces First Subject Dosed in Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury

Rhea-AI Summary

NervGen Pharma begins Phase 1b/2a trial for spinal cord injury treatment NVG-291, with results expected in mid-2024 and late 2024/early 2025 for chronic and subacute cohorts respectively.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-1.97%

Tags

09/11/2023 08:30 AM

News

NervGen Pharma to Present at 2023 International Spinal Research Trust Network Meeting

Rhea-AI Summary

NervGen Pharma's Chief Medical Officer to present at International Spinal Research Trust Network Meeting

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

3.45%

Tags

09/05/2023 08:30 AM

News

NervGen Pharma to Present on Its Drug Candidate NVG-291 and Spinal Cord Injury at the H.C. Wainwright 25th Annual Global Investment Conference

Rhea-AI Summary

NervGen Pharma to present at H.C. Wainwright conference, offering one-on-one investor meetings. Webcast available.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-4.3%

Tags

08/22/2023 08:30 AM

News

NervGen Pharma to Present on its Drug Candidate NVG-291 and Spinal Cord Injury at Investor Conference

Rhea-AI Summary

NervGen Pharma to present at KOL Discussion on Spinal Cord Injury

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-0.22%

Tags

08/09/2023 08:30 AM

News

NervGen Pharma Reports Q2 2023 Financial Results and Operational Updates

Rhea-AI Summary

NervGen Pharma Corp. reports financial and operational results for Q2 2023. Landmark Phase 1a/2b clinical trial of NVG-291 for spinal cord injury proceeds with recruitment. Results expected in mid-2024. Mike Kelly appointed as President & CEO. Grant of up to US$3.18 million awarded from Wings for Life to support clinical trial.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-1.99%

Tags

08/08/2023 08:30 AM

News

NervGen Pharma to Proceed with Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury Having Completed FDA Review and Received IRB Approval

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

8.8%

Tags

06/27/2023 08:30 AM

News

NervGen Pharma to Receive More than US$3 Million from Wings for Life to Support Upcoming Clinical Study in Spinal Cord Injury

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

7.02%

Tags

06/20/2023 04:36 PM

News

NervGen Pharma to Present at Upcoming Investor Conferences

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

2.42%

Tags

06/02/2023 06:15 PM

News

NervGen Pharma Extends the Expiry Date of Certain Stock Options

Rhea-AI Summary

NervGen Pharma Corp. has extended the expiry date of certain stock options granted to a consultant, from three years to five years following the original grant dates. The exercise price and other terms of the options remain unchanged.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.85%

Tags

FAQ

What is the current stock price of Nervgen Pharma (NGENF)?

The current stock price of Nervgen Pharma (NGENF) is $1.915 as of February 28, 2025.

What is the market cap of Nervgen Pharma (NGENF)?

The market cap of Nervgen Pharma (NGENF) is approximately 139.2M.

What is NervGen Pharma Corp focused on?

NervGen Pharma Corp is dedicated to developing innovative solutions for the treatment of nervous system damage.

What is NVG-291, and what is its current status?

NVG-291 is the lead drug candidate of NervGen Pharma Corp, currently undergoing evaluation in a Phase 1b/2a clinical trial for spinal cord injury.

What recent achievements has NervGen reported?

NervGen recently received Fast Track designation from the FDA and reported positive progress in their recruitment efforts for the clinical study.

What sets NervGen apart in the biotech industry?

NervGen's focus on enabling the nervous system to repair itself post-injury or disease and their commitment to innovative treatments differentiate them in the biotech landscape.